Europe 1 with AFP / Photo credits: Joseph Prezioso / AFP 18:43 p.m., September 14, 2023

Up to 15 new products could be launched by Moderna within five years, the group said in a statement. "The company also plans to bring up to 50 new candidates into clinical trials" over this period, continues the American laboratory.

The US laboratory Moderna plans to launch up to 15 new products over the next five years and to extend the messenger RNA technology to new applications, including oncology. "The company also plans to bring up to 50 new candidates into clinical trials" over this period, also said the group behind one of the first messenger RNA vaccines against Covid-19, in a statement published Thursday.

>> READ ALSO – "We will monitor the virus": should we worry about "Pirola", the new variant of Covid-19?

Positive opinion for updated Covid vaccine

Moderna has recorded positive Phase 3 results (the last stage of clinical trial before potential commercialization) for its influenza vaccine candidate and has filed with several countries for marketing authorization for its vaccine candidate against the respiratory RSV virus, which causes bronchiolitis.

The company received approval from US health authorities earlier this week and a positive opinion on Thursday from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its updated Covid-19 vaccine developed from the XBB.1.5 variant. The European Commission, which is responsible for approving medicines, usually aligns itself with the CHMP's recommendations within two months.

Upcoming results for a combined vaccine candidate

Moderna expects clinical results for a combined vaccine candidate (influenza and Covid-19) at the end of this year. "In the near term, we look forward to product launches in the areas of oncology, latent, rare and infectious diseases," Moderna CEO Stéphane Bancel said in the statement.

>> READ ALSO – Covid long: a patient monitoring platform planned before the end of the year

For lung cancer, the company plans to initiate in partnership with the MSD laboratory "a second phase 3 trial" later this year. Moderna has also "finalized recruitment for the Phase 3 trial of mRNA-1647, its vaccine candidate against CMV," the congenital cytomegalovirus infection. Invited by BFM Business, Stéphane Bancel said that discussions around a project to set up a Moderna factory in France were continuing with the public authorities.